---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-21-003522"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2021-08-13T23:59:59+00:00"
generated_at: "2026-06-29T11:20:10.942608+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences reports Q2 2021 net loss of $1.1M; completes $12.5M private placement

## Summary
- Net loss $1.1M for Q2 2021; cash $9.3M at quarter end.
- R&D expenses rose 70.4% to $0.5M, driven by XCART spending.
- Received ~$0.3M in royalty payments from Takeda sublicense in Q2.
- Completed $12.5M private placement in August 2021, net proceeds ~$11.4M.
- Advancing XCART personalized CAR T platform toward IND-enabling studies.

## SEC filing metadata
- accession: 0001683168-21-003522
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2021-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316821003522/0001683168-21-003522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316821003522/xenetic_i8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-21-003522
- JSON: https://secwatch.observer/filing/0001683168-21-003522.json
- Plain text: https://secwatch.observer/filing/0001683168-21-003522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.